Brief: Regulus Therapeutics Announces Receipt Of FDA Orphan Drug Designation For Rgls8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
21/06/2022 14:56
June 21 (Reuters) - Regulus Therapeutics Inc RGLS.O :
* REGULUS THERAPEUTICS ANNOUNCES RECEIPT OF FDA ORPHAN DRUG
DESIGNATION FOR RGLS8429 FOR THE TREATMENT OF AUTOSOMAL DOMINANT
POLYCYSTIC KIDNEY DISEASE (ADPKD)
Source text for Eikon: ID:nPn2sLGx0a
Further company coverage: RGLS.O
Recent news on Regulus Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Regulus Therapeutics
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview